Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
The early success of a new class of cancer drugs, revealed in test results released here over the last several days, has raised hope among the world’s top cancer specialists that they may be on the verge of an important milestone in the fight against the disease.
No comment yet.
Sign up to comment
Scoop.it!
In a modern-day clinical trial of a medicine belonging to one of the world's oldest classes of drugs, researchers have found that a drug related to aspirin and salicylate, which was first used by ancient Egyptians and Greeks to ease pain caused by inflammation, also has glucose-lowering properties and may be a potential treatment for people with type 2 diabetes, according to results presented at the American Diabetes Association's 72nd Scientific Sessions(R).
Scoop.it!
A medical treatment that uses stem cells derived from bone marrow has just been approved in Canada.
The drug, Prochymal, has already been used to treat children for a type of immune disease arising during bone marrow transplantation.
Scoop.it!
Analysis suggests stents aren't as beneficial as previously thought.
The analysis included results on more than 7,200 patients enrolled in eight studies between 1997 and 2005 comparing stents with medical therapy in stable heart patients with narrowed sections in their heart arteries.
It was time to look at updated data, according to the researchers on this case. Acting on these results could save the health care system over $9,000 per patient and cause fewer complications with the less invasive methods.
|
Scoop.it!
Over a year-long period ending in August, NEJM published 73 articles on original studies of new drugs, encompassing drugs approved by the FDA since 2000 and experimental drugs, according to a review by The Washington Post.
Of those articles, 60 were funded by a pharmaceutical company, 50 were co-written by drug company employees and 37 had a lead author, typically an academic, who had previously accepted outside compensation from the sponsoring drug company in the form of consultant pay, grants or speaker fees.
Scoop.it!
One of the great frustrations for researchers in the war on cancer is that the body’s own defense system does not do a better job fighting the disease. Tumors, it turns out, have a molecular shield that repels attacks from the immune system.
Now, a new study says, an experimental drug is showing promise in disabling that shield...
Scoop.it!
The Indian Patent Office ruled that a local generic drug maker can make and sell a knock-off of drug giant Bayer's exclusive Nexavar, a cancer drug.
This is only the second time in history that a nation has issued a compulsory license for cancer medication.
Experts believe that this may threaten the big business of global pharmaceutical firms...
Ray and Terry's 's comment,
March 19, 2012 4:21 PM
Does this ruling matter to the poorest patients?
http://www.reuters.com/article/2012/03/18/us-india-drugs-cancer-idUSBRE82H01A20120318
Scoop.it!
Many people now use pharmaceuticals to help manage their moods. Anxiety is commonplace in a world where everything moves quickly and multi-tasking is a necessity.
Are there other options?
Possibly. New research lends credence to the use of two natural supplements for depression and anxiety.
|
